Phenolic compounds

Other Names

AcetophenonesAnthocyaninsBioactive phenolic compoundsBioactive phenolicsChromonesCondensed tanninsCoumarinsDietary phenolicsDietary polyphenolsFlavonoidsHydrolyzable tanninsHydroxybenzene derivativesHydroxycinnamic acid derivativesHydroxylated aromatic compoundsIsoflavonoidsLignansLigninsNaphthoquinonesNatural phenolic compoundsNeolignansPhenol derivativesPhenolic acidsPhenolic alcoholsPhenolic ketonesPhenolic metabolitesPhenolic phytochemicalsPhenolic secondary metabolitesPhenolicsPhenylacetic acidsPhenylpropanoidsPhenylpropionic acidsPhytochemicalsPhytophenolsPlant phenolicsPlant polyphenolsPlant secondary metabolitesPolyhydroxy phytochemicalsPolyphenolic compoundsPolyphenolsProanthocyanidinsSecondary metabolitesSimple phenolsStilbenesStilbenoidsTanninsXanthones

Synopsis

Phenolic Compounds (Polyphenols): A Comprehensive Reference

1. Identity, Chemistry, and Classification

1.1 Chemical Definition

Polyphenols, also known as phenolic compounds, are chemical substances containing aromatic rings as well as at least two hydroxyl groups. Natural phenolic compounds exist widely in plants. They are a large family of naturally occurring phenols that are abundant in plants and structurally diverse. The name derives from the Ancient Greek word πολύς (polus, meaning "many, much") and the word "phenol," which refers to a chemical structure formed by attachment of an aromatic benzenoid (phenyl) ring to a hydroxyl (–OH) group. The term "polyphenol" has been in use at least since 1894.

Phenolic compounds are the most abundant secondary metabolites in plants, showing a wide range of distinct biological activities. Natural phenolic compounds protect plants from ultraviolet radiation and other insults. Plants produce secondary metabolites such as polyphenols to protect themselves from the plethora of biotic and abiotic stresses.

1.2 Principal Classification

Polyphenols are natural products with "several hydroxyl groups on aromatic rings," including four principal classes: phenolic acids, flavonoids, stilbenes, and lignans. More detailed taxonomies expand this further: phenolic compounds from medicinal herbs and dietary plants include phenolic acids, flavonoids, tannins, stilbenes, curcuminoids, coumarins, lignans, quinones, and others.

Polyphenols, according to their chemical structure, are divided into sub-groups: phenolic acids (hydroxybenzoic and hydroxycinnamic acids), flavonoids (flavonols, flavones, flavanones, flavanonols, isoflavones, anthocyanidins, tannins), stilbenes (resveratrol), and lignans found in plants and foods of plant origin.

Phenolic Acids: Phenolic acids are one of the main classes of phenolic compounds found in plants and occur in the form of esters, glycosides, or amides, but rarely in free form. The structural variation of phenolic acids depends on the number and position of hydroxyl groups on the aromatic ring. Phenolic acids have two distinctive structures: the hydroxycinnamic and hydroxybenzoic acid.
Flavonoids: The largest and most studied subclass, encompassing flavonols (quercetin, kaempferol), flavones, flavanones (hesperidin), flavanonols, isoflavones (genistein, daidzein), anthocyanidins (cyanidin), and flavan-3-ols (catechins, including EGCG from green tea).
Stilbenes: Best represented by resveratrol, found notably in red grape skins and wine.
Lignans: Found in flaxseed, sesame, and various grains; enterolactone is a key mammalian lignan metabolite produced by gut bacteria.
Tannins: Including condensed tannins (proanthocyanidins) and hydrolysable tannins (ellagitannins); the most abundant polyphenols are the condensed tannins, found in virtually all families of plants.
Curcuminoids and Coumarins: Also classified under phenolic compounds, with curcumin from Curcuma longa being the most prominent curcuminoid.

1.3 Natural Sources

The main sources of phenolic compounds are fruits and vegetables, but more and more studies refer to woody vascular plants, especially to bark, as an important source of phenolic compounds with a potential biological effect. Phenolic compounds including phenolic acids, flavonoids, and proanthocyanidins are widely distributed in plants as a protective mechanism against biotic and abiotic stresses. Fruits, vegetables, grains, spices, and herbs are the richest source of dietary polyphenols.

Our diet includes grains, cereals, pulses, vegetables, spices, fruits, chocolates, and beverages like fruit juices, tea, coffee, and wine as typical sources. Specific food sources include:

Beverages: Green tea (rich in catechins/EGCG), black tea, coffee (chlorogenic acids), red wine (resveratrol, quercetin, anthocyanins)
Fruits: Berries (anthocyanins), citrus (flavanones such as hesperidin), apples, cherries, grapes, pomegranate
Vegetables: Onions (quercetin), artichokes (flavones), spinach and beans (flavonols), olives (hydroxytyrosol, oleuropein)
Nuts, seeds and oils: Flaxseed (lignans), walnuts, extra-virgin olive oil (secoiridoids and tyrosols)
Spices and herbs: Turmeric (curcuminoids), cloves, rosemary
Chocolate and cocoa: Flavan-3-ols (procyanidins)
Legumes: Soy (isoflavones: genistein, daidzein)

There is significant variation in phenolic content across different food sources, and the impact of processing methods is notable, with germination being a key strategy for enhancing the nutritional and bioactive value of cereals and legumes.

1.4 Common Forms and Preparations

Phenolic compounds are commercially available and consumed in several forms:

Whole foods and beverages: The primary mode of population-level exposure
Standardized plant extracts: Concentrated preparations of grape seed extract, green tea extract, olive leaf extract, resveratrol, quercetin, and others
Isolated individual compounds: Pure resveratrol, quercetin, curcumin, and EGCG, sold as dietary supplements
Nanoformulations (investigational): The bioavailability of lipophilic compounds such as resveratrol and quercetin is being addressed by their encapsulation in different formulations, such as liposomes, nanoemulsions, polymeric micelles, nanoparticles, and dendrimers.

2. Traditional and Historical Use

Natural products have been considered since ancient times as an important source of bioactive compounds with therapeutic potential. Since ancient times, plants have played an important role for humanity, for example as food, clothing, perfumes, and/or medicines.

The compounds found in plants are diverse, with most in four biochemical classes: alkaloids, glycosides, polyphenols, and terpenes. Polyphenol-rich plants were central to the oldest recorded materia medica: the earliest historical records of herbs are found from the Sumerian civilization, where hundreds of medicinal plants are listed on clay tablets, c. 3000 BC. The Ebers Papyrus from ancient Egypt, c. 1550 BC, describes over 850 plant medicines. The Greek physician Dioscorides documented over 1,000 recipes for medicines using over 600 medicinal plants in De materia medica, c. 60 AD; this formed the basis of pharmacopeias for some 1,500 years.

Humans have long used traditional medicines, using them since ancient times, especially in Asian countries. In Traditional Chinese Medicine, Ayurveda, and indigenous herbal traditions worldwide, polyphenol-rich plants were prepared as decoctions, teas, tinctures, and poultices for purposes ranging from wound healing and anti-infective treatment to treatment of fevers, digestive complaints, and pain. Resveratrol-containing plants (including grape vine roots and Polygonum cuspidatum) have been used in Japanese and Chinese traditional medicine (Itadori tea) for centuries for cardiovascular and inflammatory complaints. Turmeric (curcuminoids) has been employed in Ayurvedic medicine for millennia as an anti-inflammatory and digestive agent. Quercetin-rich plants such as elderflower and oak bark were widely used in European folk medicine.

Some polyphenols are traditionally used as dyes in leather tanning. For instance, in the Indian subcontinent, pomegranate peel, high in tannins and other polyphenols, or its juice, is employed in the dyeing of non-synthetic fabrics.

Though ubiquitous in nature, polyphenols gained scientific prominence only after the pioneering work of researchers like E. Fischer and K. Freudenberg, who demonstrated their potential beyond traditional applications, such as in the leather industry. Already in 1978, the World Health Organization (WHO) highlighted the need for scientific research in traditional medicine. Since then it has begun to put in value this type of medicine, as well as to investigate the efficacy of the mechanism of action and chemical bases of traditional herbal medicine for the development of new drugs.

Among these bioactive compounds are polyphenols, secondary metabolites from different plant species that represent the largest group of non-energy compounds in foods of plant origin. Different epidemiological studies have correlated the high consumption of cereals, fruits, and vegetables that characterize the Mediterranean diet, among others, with a lower risk of developing certain diseases. The intake of polyphenols has been shown to be beneficial for health, reducing the risk of cancer, cardiovascular diseases, neurodegenerative diseases, and other degenerative diseases.

3. Key Constituents and Active Compounds

The phenolic compound family is extraordinarily diverse. The most extensively studied individual members include:

Quercetin (flavonol): One of the most abundant dietary flavonoids; found in onions, apples, capers, and berries. Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is a flavonoid and polyphenol found in high concentrations in several plants and fruits.
Epigallocatechin gallate (EGCG): The principal catechin in green tea; extensively studied for antioxidant and anti-cancer properties.
Resveratrol (stilbene): Found in grape skins, red wine, and Japanese knotweed; studied for cardiovascular and neuroprotective effects.
Curcumin (curcuminoid): The principal polyphenol of turmeric (Curcuma longa); among the most studied natural anti-inflammatory compounds.
Kaempferol and Myricetin (flavonols): Found in leafy greens, broccoli, and berries.
Anthocyanins (e.g., cyanidin-3-glucoside): Responsible for red/blue/purple pigmentation in berries, cherries, and red cabbage.
Chlorogenic acid: A major hydroxycinnamic acid and the principal polyphenol in coffee.
Hydroxytyrosol and oleuropein: Tyrosols specific to olive oil and olive leaves.
Genistein and daidzein (isoflavones): Phytoestrogenic compounds in soy and other legumes.
Enterolactone (lignan metabolite): Produced by intestinal bacteria from dietary lignans; subject of several prospective CVD studies.

The phenolic compounds found in plants in high concentrations perform a wide range of beneficial biological functions; however, poor stability, poor solubility, and limited bioavailability significantly limit the utilization of these compounds in food and medicine.

4. Mechanisms of Action

4.1 Antioxidant Activity

Dietary polyphenols act as efficient free radical and reactive oxygen species (ROS) scavengers, owing to the presence of aromatic structural features, multiple hydroxyl groups, and a highly conjugated system. They have the capability to negate ROS or to suppress cellular oxidative stress, enabling them to avert oxidative damage of biomolecules (lipids, proteins, DNA) and thereby diminish tissue inflammation.

Some chemical properties such as acidity and formation of radicals are directly linked with important and key biological activities such as antioxidant properties. Phenols can protect key cellular components from reactive free radical damage, which is mainly due to their property to activate antioxidant enzymes and alleviate oxidative stress and inflammation.

4.2 Anti-inflammatory Signaling (NF-κB and Nrf2 Pathways)

Reactive oxygen species play leading roles in provoking pan-cellular inflammation, mediated by the activation of powerful transcription factors such as nuclear redox factor-2 (Nrf2), nuclear factor-kappa B (NF-κB), and activator protein 1. Under unstressed conditions, inactive Nrf2 is linked to its cytoplasmic regulator. Due to reactive species accumulation in cells, Nrf2 dissociates, translocates into the nucleus, and modulates antioxidant-responsive elements-mediated transcription of cytoprotective genes. Phenolic compounds are able to enhance protective pathways by activating Nrf2.

Polyphenols alleviate inflammation and cell apoptosis by promoting the microbial production of short-chain fatty acids (SCFAs), which subsequently modulate the NF-κB and AMPK signaling pathways.

The ability of dietary polyphenols to suppress inflammation and consequently oxidative damage to tissues is mediated through their antioxidant effects, interference with signaling pathways of oxidative stress, and suppression of signaling transduction mechanisms of pro-inflammatory mediators and cellular inflammatory pathways at the molecular level.

4.3 Cardiovascular and Vascular Effects

There are numerous mechanisms through which polyphenols can influence the complex pathophysiology of cardiovascular disease (CVD); these include decreasing blood pressure, reducing cholesterol levels, acting as antioxidants, mitigating inflammation, inhibiting cell proliferation and angiogenesis, promoting endothelial function recovery, preventing thrombosis, and providing protection for the myocardium, among other functions.

Historically, biologic actions of polyphenols have been attributed to antioxidant activities, but recent evidence suggests that immunomodulatory and vasodilatory properties of polyphenols may also contribute to CVD risk reduction. Recent studies indicate that polyphenols also exert beneficial effects on vascular disorders by blocking platelet aggregation as well as by preventing oxidation of low-density lipoprotein (LDL), ameliorating endothelial dysfunction, reducing blood pressure, improving antioxidant defenses, and alleviating inflammatory markers.

4.4 Anticancer Mechanisms

Various bioactivities of phenolic compounds are responsible for their chemopreventive properties (e.g., antioxidant, anticarcinogenic, or antimutagenic and anti-inflammatory effects) and also contribute to their inducing apoptosis by arresting cell cycle, regulating carcinogen metabolism and oncogene expression, inhibiting DNA binding and cell adhesion, migration, proliferation or differentiation, and blocking signaling pathways.

These polyphenols can exert anticancer effects through a broad range of mechanisms, including cancer cell removal by modification of signaling pathways, inhibition of cell cycle events, and apoptosis induction. Polyphenols also regulate the activities of enzymes involved in tumor cell proliferation. Recent studies are implicating natural polyphenols and their anti-cancer potential through a wide range of properties, e.g., antiangiogenic, antimetastasis, DNA-interaction, and others.

4.5 Antidiabetic Mechanisms

The mechanisms of phenolic compounds' antioxidant and anti-inflammatory properties are linked with their capacity to scavenge free radicals, restore antioxidant enzyme activity, and regulate cytokine-induced inflammation. The suppression of gluconeogenesis in the liver and increase in glucose uptake in peripheral tissues, through the modulation of intracellular signaling pathways, are other proposed mechanisms of polyphenols' activity. These compounds have a high therapeutic potential for diabetes management, and their mode of action includes several mechanisms related to oxidative stress reduction, the inhibition of DPP-IV and enzymes involved in carbohydrate metabolism, a reduction in insulin resistance, and AGE (advanced glycation end-product) formation, among others.

4.6 Neuroprotective Mechanisms

Recent studies have shown that polyphenols can prevent neurodegenerative diseases by affecting cerebral blood flow, neurogenesis, synaptic plasticity, protein aggregation, mitochondrial dysfunction, neuroinflammation, and oxidative stress in the central nervous system (CNS). Polyphenols have shown promise in modulating various cellular signaling pathways associated with neuronal viability, synaptic plasticity, and cognitive function, including key pathways such as Akt, Nrf2, STAT, and MAPK, which play critical roles in neuroprotection and the body's immune response.

Their activity in the brain encompasses the prevention of neuronal fatty acids' oxidation, a reduction in the damage caused by reactive oxygen and nitrogen species, and an improvement in neurocognition by facilitating de novo protein synthesis in key sites and neurogenesis in the dentate gyrus.

4.7 Gut Microbiota Modulation and Bioavailability

Free polyphenols, constituting about 5–10% of total phenols, can be readily absorbed in the small intestine. However, the remaining 90–95% are bound polyphenols that reach the colon, where intestinal microbes break them down into small-molecule metabolites prior to entering the gut and liver blood circulation. Polyphenols may also undergo conjugation reactions within the gut or enterocytes, affecting their bioavailability and bioactivity.

The limited absorption of polyphenols in the small intestine means that most phenolics pass into the colon, where they interact with gut microbiota. These microorganisms biotransform polyphenols into bioactive metabolites, such as SCFAs and phenolic acids, which further enhance antioxidant activity. The reciprocal relationship between polyphenols and gut flora is critical in maintaining gut health and reducing ROS-related damage. Polyphenols promote the growth of beneficial bacteria like Lactobacillus and Bifidobacterium while inhibiting harmful species, thus supporting a healthy gut environment.

5. Dietary Intake and Epidemiological Data

Population-level intake data from several large cohorts using the Phenol-Explorer database have quantified typical polyphenol consumption:

In the PREDIMED study, a large parallel-group, multicentre, randomised, controlled 5-year feeding trial, a total of 7,200 participants aged 55–80 years completed a validated 1-year food frequency questionnaire at baseline. Polyphenol consumption was calculated using the Phenol-Explorer database. The mean total polyphenol intake was 820 ± 323 mg day⁻¹ (443 ± 218 mg day⁻¹ of flavonoids and 304 ± 156 mg day⁻¹ of phenolic acids). Hydroxycinnamic acids were the phenolic group with the highest consumption, and 5-caffeoylquinic acid was the most abundantly ingested individual polyphenol.

In the Mediterranean Healthy Eating, Aging and Lifestyle (MEAL) study, a total of 1,937 individuals completed a validated 110-item food frequency questionnaire. Mean intake of polyphenols was 663.7 mg/d; the most abundant classes were phenolic acids (362.7 mg/d) and flavonoids (258.7 mg/d). The main dietary sources of total polyphenols were nuts, followed by tea and coffee as sources of flavanols and hydroxycinnamic acids, respectively, fruits (cherries as sources of anthocyanins and citrus fruits of flavanones) and vegetables (artichokes and olives as sources of flavones, spinach and beans of flavonols); chocolate, red wine, and pasta contributed to flavanols and tyrosols, respectively.

In a Northern European population (Polish arm of the HAPIEE study), the mean intake of polyphenols was 1,756.5 ± 695.8 mg/d. The main food contributors to polyphenol intake were mostly nonalcoholic beverages (such as tea and coffee) that accounted for 67% of the total polyphenol intake (about 1,000 mg/d), followed by chocolate, apples, and vegetable oils. Coffee was the main food source of hydroxycinnamic acids, whereas tea was the main dietary source of flavonoids.

In Mediterranean countries such as Spain, the main dietary source of polyphenols is coffee and fruits, but the most important differentiating factor with respect to other countries is the consumption of polyphenols from olives and olive oil.

6. Scientific Evidence by Health Area

6.1 Cardiovascular Disease

Epidemiological Evidence: There is strong epidemiological evidence linking regular consumption of phenolic compounds to a reduced risk of chronic diseases such as cardiovascular disease, cancer, and obesity.

In the PREDIMED study data, over an average of 4.3 years of follow-up among 7,172 participants, there were 273 confirmed cases of CVD. After multivariate adjustment, a 46% reduction in risk of CVD was observed comparing the highest versus lowest quintile of total polyphenol intake (HR = 0.54; 95% CI = 0.33–0.91; P-trend = 0.04).

Biomarker Studies (Observational): In a systematic review of eight observational studies investigating 16 different polyphenol biomarkers in association with CVD and mortality, blood and urine were used as biospecimens, and enterolactone, a lignan metabolite, was most often investigated. Three meta-analyses were conducted investigating the association between enterolactone and all-cause and CVD mortality, and non-fatal myocardial infarction. A 30% and 45% reduced all-cause and CVD mortality risk were revealed at higher enterolactone concentrations.

Clinical Trials and Systematic Reviews: A systematic review examined the scientific evidence supporting phenolic compound efficacy in CVD prevention and treatment, including all randomized controlled trials (RCTs) with prospective, parallel or crossover designs in humans where the effects were compared with placebo/control. Vascular homeostasis, blood pressure, endothelial function, oxidative stress, and inflammatory biomarkers were considered as primary outcomes. The review selected 72 articles and verified their quality. Evidence shows that certain polyphenols, such as flavonols, can be helpful in decreasing CVD risk factors. However, further rigorous evidence is necessary to support the effect on CVD prevention and treatment.

Several studies have demonstrated that polyphenol-enriched diets may have beneficial effects against the development of degenerative diseases, including atherosclerosis. This activity has been associated not only with antioxidant and anti-inflammatory properties, but also with additional mechanisms, such as the modulation of lipid metabolism and gut microbiota function. However, long-term studies on humans have provided controversial results, making the prediction of polyphenol impact on health uncertain.

Evidence Strength: Epidemiological associations are encouraging, and RCTs show favorable effects on surrogate markers (endothelial function, blood pressure, LDL oxidation). However, as of the current evidence base, most evidence was derived from in vitro or animal studies, while human trials that evaluate long-term effects of polyphenols are particularly scant. Moreover, no studies with hard clinical end points have been conducted so far.

6.2 Type 2 Diabetes and Glycemic Control

Polyphenols may influence glycemia and type 2 diabetes (T2D) through different mechanisms, such as promoting the uptake of glucose in tissues, and therefore improving insulin sensitivity. Intakes of polyphenols, especially flavan-3-ols, and their food sources have demonstrated beneficial effects on insulin resistance and other cardiometabolic risk factors. Several prospective studies have shown inverse associations between polyphenol intake and T2D. The Mediterranean diet and its key components, olive oil, nuts, and red wine, have been inversely associated with insulin resistance and T2D.

In clinical studies, biomarkers such as blood glucose, fasting insulin, or HbA1c were reported to be affected by a specific polyphenol but not another in some meta-analyses. Pre-clinical data have confirmed polyphenols as chemicals having metabolic regulation effects that may help to prevent or postpone the onset of T2D, although human evidence is still lacking. There have only been a few meta-analyses of randomized controlled human studies examining the impact of polyphenols on diabetes biomarkers or incidence, and some of them have shown confusing results. Many experiments with green tea and similar catechins have been conducted, but the findings have not been consistent.

Evidence Strength: Mechanistic evidence (preclinical) is strong. Epidemiological data are supportive. Clinical trial data are promising but inconsistent; the field lacks sufficiently powered long-term RCTs with standardized polyphenol interventions.

6.3 Neurodegenerative Disease and Cognitive Function

Polyphenolic extracts from grapes and blueberries can improve memory in older individuals with initially lower memory performance. Epidemiological and clinical studies highlight the potential of polyphenol-rich diets to decrease the risk and alleviate symptoms of neurodegenerative disorders and neuroinflammation.

In a notable clinical example, patients with Alzheimer's disease supplemented with genistein at a dose of 120 mg/day for 12 months exhibited a significant improvement in two of the tests used. In genistein-treated patients, amyloid-beta deposition analysis revealed that they did not increase their uptake in the anterior cingulate gyrus after treatment, as opposed to the placebo-treated group for which an increase was noted.

Recent studies have reported the role of gut microbiota and its interaction with the microbiome-gut-brain axis (MGBA) in neurodegenerative disorders. Dietary polyphenols possess antioxidant and anti-inflammatory properties, which might modulate gut microbiota and attenuate the progression of neurodegenerative diseases by acting on the MGBA. A systematic review (following PRISMA guidelines) evaluated the effects of polyphenols on gut microbiota, their metabolites, and gut microbiota-related mechanisms in such disorders.

Possible explanations for discrepancies in results are bioavailability issues and inter-individual variability of gut microbiota composition and function, so that the same polyphenols may translate in different effects on people, depending on individual characteristics. In summary, the lack of convincing results from clinical trials makes it difficult to draw a solid conclusion on their preventive effects on cognitive status and neurodegeneration.

Evidence Strength: Preliminary but growing. Animal and in vitro evidence is robust; select clinical trials show favorable signals but results are mixed. Bioavailability across the blood-brain barrier remains a major constraint.

6.4 Cancer Prevention

Numerous studies have shown that the consumption of polyphenols yields various health benefits, including antiviral, antioxidant, anti-inflammatory, anti-thrombogenic, anti-allergic, antihyperlipidemic, anti-diabetic, anti-asthma, and anticancer effects.

There is promising evidence for the in vitro and in vivo anticancer activity of many polyphenols, including resveratrol and quercetin, specifically in the treatment of colorectal cancer (CRC). There is a clear association between resveratrol and quercetin in interfering with mechanistic pathways involved in CRC, such as Wnt, P13K/AKT, caspase-3, MAPK, NF-κB, etc. The therapeutic potential of resveratrol and quercetin is well established by their abilities to reduce tumor growth, inhibit metastasis, and increase apoptotic, anti-inflammatory, and antioxidant pathways.

Evidence Strength: The evidence base remains predominantly preclinical (cell lines and animal models). Many studies focusing on the health benefits of flavonoids and other polyphenols have been tested using in silico, in vitro, and in vivo models. However, few studies have been carried out using clinical trials that have trustworthy subject sizes and are in accordance with clinical practice guidelines. Translation to human benefit from dietary or supplemental polyphenol use for cancer prevention or treatment has not been conclusively demonstrated in large RCTs.

6.5 Inflammatory Bowel Disease (IBD)

Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are a rapidly growing public health concern worldwide. These diseases characteristically involve a disrupted immune-microbiome axis. Shortcomings in conventional treatment options warrant the need for novel therapeutic strategies to mitigate these life-long and relapsing disorders of the gastrointestinal tract. Polyphenols, a diverse group of phytochemicals, have gained attention as candidate treatments due to their array of biological effects. Polyphenols exert broad anti-inflammatory and antioxidant effects through the modulation of cellular signaling pathways and transcription factors important in intestinal homeostasis. Evidence in this area is emerging but human clinical trials remain limited in number and scale.

6.6 Hypertension

In a cohort study using the Mediterranean population, the mean intake of total phenolic acids was 362.6 mg/day. Individuals in the highest quartile of phenolic acid intake (median intake = 522.2 mg/day) were less likely to have hypertension (OR = 0.68, 95% CI: 0.46, 1.00). When taking into account individual subclasses of phenolic acids, only hydroxyphenylacetic acid was inversely associated with hypertension.

Kaempferol, quercetin, and resveratrol prevent oxidative stress by regulating proteins that induce oxidation in heart tissues. RCT-level evidence for blood pressure reduction from specific polyphenols (cocoa flavanols, quercetin) exists but trials are generally short-term and in specific populations.

7. Body Systems and Health Areas

Current literature suggests that the long-term consumption of diets rich in polyphenols protects against certain cancers, cardiovascular diseases, type 2 diabetes, osteoporosis, pancreatitis, gastrointestinal problems, lung damage, and neurodegenerative diseases. The organ systems most prominently studied include:

Cardiovascular system: Endothelial function, blood pressure, lipid oxidation, platelet aggregation, thrombosis
Central nervous system: Neuroprotection, cognitive function, neuroinflammation, Alzheimer's and Parkinson's diseases
Gastrointestinal tract: Gut microbiota modulation, IBD, colorectal cancer, intestinal barrier integrity
Metabolic/endocrine system: Insulin sensitivity, glycemic control, adipogenesis, obesity
Immune system: Modulation of pro-inflammatory cytokines, NF-κB suppression, antimicrobial/antiviral activity
Musculoskeletal system: Bone health (osteoporosis), exercise recovery
Liver: Hepatoprotective effects, non-alcoholic fatty liver disease

Today, these bioactive compounds are recognized for their diverse therapeutic roles, including their use as adjuvants in cancer treatment, cancer prevention, and their anti-inflammatory and antioxidant properties. Additionally, polyphenols have demonstrated benefits in managing obesity, cardiovascular diseases, and neuromodulation.

8. Dosage Forms and Doses Reported in Studies

Because phenolic compounds comprise hundreds of individual molecules, there is no single "standard" supplement dose applicable to all. Doses in published studies vary considerably by compound and indication:

Genistein (isoflavone): Patients with Alzheimer's disease were supplemented with genistein at a dose of 120 mg/day for 12 months in one reported clinical trial.
Resveratrol: A randomized clinical trial on adults with T2D used supplementation with resveratrol at two doses: 1,000 mg/day and 500 mg/day.
Green Tea Extract (GTE): The effect of GTE supplementation was monitored in 46 obese patients in a randomized, double-blind, placebo-controlled study. Patients received either 379 mg of GTE or a placebo, daily for three months.
Population-level dietary intake: As measured in Mediterranean cohorts, mean total polyphenol consumption from diet ranges from approximately 660 mg/day to over 820 mg/day, with Northern European populations consuming over 1,700 mg/day primarily from tea and coffee.
Iron-inhibition study (polyphenol supplement): A PPS mixture precipitated approximately 80% of iron when 2 g was added to a 500 g iron solution. In the iron absorption study in hereditary hemochromatosis patients, the PPS reduced fractional iron absorption by approximately 40%.

Despite their promising biological activities, a significant limitation of polyphenols lies in their inherently low oral bioavailability. Bioavailability of quercetin, for example, has been reported at 17% in rats and a mere 1% in humans. These constraints mean that effective supplement doses are often studied at levels well above typical dietary intake, and whether such supraphysiological doses are safe and effective long-term in humans has not been fully established.

Efforts to address bioavailability limitations include nanoformulation strategies: an overview of nanosystem categories includes lipid-based nanocarriers, such as liposomes, nanostructured-lipid carriers, and solid-lipid nanoparticles, which are widely used to improve oral absorption and targeting, increase antioxidant activity, and ensure sustained release.

9. Safety Considerations and Drug Interactions

9.1 General Safety Profile

As with any chemical substance, depending on the conditions, dose, and interactions with the environment, it is possible for polyphenols to also exert harmful effects. A comprehensive review of knowledge on the negative impact of polyphenols on human health describes the possible side effects of polyphenol intake, especially in the form of supplements.

The review covers: the consequences of polyphenols' ability to block iron uptake, which in some subpopulations can be harmful, as well as the possible inhibition of digestive enzymes, inhibition of intestinal microbiota, interactions of polyphenolic compounds with drugs, and impact on hormonal balance. Additionally, the pro-oxidative activity of polyphenols, as well as their mutagenic, carcinogenic, and genotoxic effects at high doses, are documented concerns warranting attention.

9.2 Iron Absorption Inhibition

Polyphenolic compounds are very strong inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron in the gastrointestinal tract that cannot be absorbed. Drinking beverages that contain 20–50 mg total polyphenols per serving caused a reduction in iron absorption from a bread meal by 50–70% (compared to drinking water), whereas beverages containing 100–400 mg total polyphenols per serving reduced iron absorption by 60–90%. The most potent inhibitors of iron absorption were black teas (79–94%), peppermint tea (84%), pennyroyal (73%), and cocoa (71%).

This property may be clinically significant in individuals at risk for iron deficiency. Conversely, this same property has been explored therapeutically: a natural polyphenol supplement was shown in European subjects with hereditary hemochromatosis to reduce iron absorption by approximately 40%. Decreasing non-heme iron absorption in adults with iron-loading conditions could potentially lead to an extension of the time period between phlebotomies or chelation therapies.

9.3 Drug Interactions

Statins: Polyphenols significantly influenced statin pharmacokinetics, altering total drug exposure (AUC) and extent (Cmax), either by enhancement or inhibition, with apparently less impact on absorption rate (Tmax). At the clinical level, only five studies addressed statin-polyphenol interactions, yielding conflicting results on the potential enhancement of therapeutic efficacy and adverse effects. There is substantial inter-individual variability linked to conflicting evidence, from synergistic effects enabling lower statin doses and reduced adverse events to potential exacerbation of side effects.

General interaction concern: In some cases, supplementation trials of antioxidants have been associated with adverse effects, including increased mortality or stroke in some studies. Concerns regarding heterogeneous effects in subpopulations and interactions with medications also arise with the promotion of polyphenol consumption at levels far above natural occurrence.

9.4 Hormonal Effects

Isoflavones (genistein, daidzein) are structurally similar to estrogens and bind to estrogen receptors. This phytoestrogenic activity has been studied in the context of menopausal symptom relief and breast cancer risk, though evidence on net hormonal effects, particularly with supplemental rather than dietary doses, remains debated. Without a complete understanding of the safe and beneficial levels of polyphenol intake, their fortification in foods cannot be adequately informed.

9.5 Bioavailability and Instability

The main factors that limit polyphenol therapeutic efficacy are: selective permeability across the blood-brain barrier (dependent on stereochemistry, interactions with efflux transporters, the degree of lipophilicity, the form of administration, and synergistic effects), gastrointestinal transformations, poor absorption, rapid hepatic and colonic metabolism, and systemic elimination. The most usual oral administration also conflicts with bioavailability. Thus, phenolic compounds have inadequate bioavailability for human applications to have any beneficial effects in many contexts. In addition, since polyphenols are sensitive to a great number of physiological conditions, for effective clinical applications, their stability must be improved.

9.6 Pro-oxidant Activity at High Doses

In some cases, supplementation trials of antioxidants have been associated with adverse effects, including increased mortality or stroke in some studies. At very high, non-physiological concentrations, polyphenols can act as pro-oxidants rather than antioxidants—a phenomenon observed in vitro that underscores the importance of dose in determining net biological effect. Researchers should be extremely cautious before undertaking supplementation trials of polyphenolic compounds at doses far exceeding normal dietary exposure, given this biphasic dose-response behavior.

References

Health Conditions

Health conditions that Phenolic compounds may help support.

No conditions available.

Body Systems

Body systems that Phenolic compounds may help support.

No body systems available.